Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synvista Therapeutics and Novel Therapeutic Technologies have entered into an agreement under which Novel will provide Synvista with formulation work for a topical cream formulation of ALT-2074 for the treatment of psoriasis.
Subscribe to our email newsletter
ALT-2074 is one of the company’s lead compounds under development for use in cardiovascular disease.
Noah Berkowitz, president and CEO of Synvista Therapeutics, said: “We have identified sites in Israel to perform a planned Phase II clinical trial for plaque psoriasis beginning mid-2008, pending approval from the Ministry of Health in Israel. Based on our current timeline, assuming timely receipt of regulatory approval, we hope to announce study results in the fourth quarter of 2008.”